Uniqure NV (NASDAQ:QURE) shares fell 11% during mid-day trading on Wednesday . The stock traded as low as $22.25 and last traded at $22.36. 729,774 shares were traded during mid-day trading, an increase of 85% from the average session volume of 393,799 shares. The stock had previously closed at $25.11.
Several brokerages have recently issued reports on QURE. Zacks Investment Research cut Uniqure from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. HC Wainwright began coverage on Uniqure in a research note on Friday, December 1st. They issued a “buy” rating and a $28.00 price objective for the company. Oppenheimer restated a “hold” rating on shares of Uniqure in a research note on Friday, November 24th. BidaskClub cut Uniqure from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Finally, ValuEngine upgraded Uniqure from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the stock. Uniqure has a consensus rating of “Buy” and a consensus price target of $20.75.
The company has a debt-to-equity ratio of 0.73, a current ratio of 3.64 and a quick ratio of 3.64. The firm has a market cap of $688.69, a P/E ratio of -8.57 and a beta of 0.09.
In related news, SVP Maria E. Cantor sold 5,864 shares of Uniqure stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $20.13, for a total transaction of $118,042.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 21,690 shares of Uniqure stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $19.87, for a total value of $430,980.30. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,510 shares of company stock valued at $815,776. 0.73% of the stock is owned by company insiders.
A number of hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new position in Uniqure during the fourth quarter valued at approximately $119,000. Perceptive Advisors LLC raised its position in Uniqure by 0.8% during the fourth quarter. Perceptive Advisors LLC now owns 1,047,950 shares of the biotechnology company’s stock valued at $20,529,000 after acquiring an additional 7,831 shares in the last quarter. Ellington Management Group LLC purchased a new position in Uniqure during the fourth quarter valued at approximately $237,000. Goldman Sachs Group Inc. purchased a new position in Uniqure during the fourth quarter valued at approximately $373,000. Finally, Virtus Fund Advisers LLC purchased a new position in Uniqure during the fourth quarter valued at approximately $389,000. Institutional investors own 44.05% of the company’s stock.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.